Merck KGaA
Exscientia enters AI drug discovery collaboration with Merck KGaA
September 20, 2023Business Services AI, Exscientia, Immunology, Merck KGaA, Neurology, Oncology, collaboration, drug discovery
Exscientia has announced a new collaboration with Merck KGaA, Darmstadt, Germany, with a focus on the discovery of novel small …
Merck KGaA’s cancer drug Bavencio gets EU approval
January 25, 2021Sales and Marketing Merck KGaA
The EC has approved Merck KGaA’s BAVENCIO (avelumab) as monotherapy for the first-line maintenance treatment of adult patients with locally …
Company veteran Belén Garijo named as Merck KGaA’s first-ever female CEO
September 30, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Merck KGaA
German pharma firm Merck KGaA has taken the decision to appoint its first female Chief Executive Officer in its 352-year …
Bavencio Phase 3 head and neck cancer trial terminated
March 16, 2020Research and Development, Sales and Marketing Bavencio, Cancer, EMD Serono, Merck KGaA, Pfizer, trial failure
Merck KGaA, its biopharma division EMD Serono, and Pfizer have announced their decision to terminate their ongoing Phase 3 trial …
Merck KGaA to flog Allergopharma business to Dermapharm
February 21, 2020Medical Communications, Sales and Marketing Allergopharma, Dermapharm, Merck KGaA, pharma
German-based drugmaker Merck KGaA has confirmed its intention to divest its allergy business Allergopharma to Dermapharm, another German manufacturer of …
Realising the potential of greater collaboration for women living with cancer
January 27, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Merck KGaA, feature, pharma, women
Following the launch of a new global report, ‘Supporting women with cancer’, Lynn Talyroe, Senior Vice President, Head of Healthcare …
Bavencio extends survival at Phase 3 in previously untreated locally advanced or metastatic urothelial carcinoma
January 7, 2020Manufacturing and Production, Research and Development Bavencio, Merck KGaA, Pfizer, pharma
Bavencio (avelumab), the anti-programmed death ligand-1 (PD-L1) antibody co-developed by Pfizer and Merck KGaA’s biopharma unit EMD Serono, has been …
New report reveals shocking knowledge gaps around type 2 diabetes risk factors
November 14, 2019Medical Communications, Research and Development Merck KGaA, diabetes, pharma, type 2 diabetes
A new report released on World Diabetes Day has shone a light on a startling lack of knowledge surrounding type …
Pfizer and Merck KGaA’s Bavencio falls short of primary endpoint in Phase 3 gastric cancer trial
November 8, 2019Medical Communications, Research and Development Bavencio, Merck KGaA, Pfizer, pharma
Pfizer and Merck KGaA’s EMD Serono have lifted the lid on new Phase 3 data for Bavencio (avelumab) in the …
Bavencio+Inlyta combo OK’d in Europe for first-line advanced kidney cancer
October 29, 2019Manufacturing and Production, Sales and Marketing Bavencio, Cancer, Kidney cancer, Merck KGaA, Pfizer, inlyta, pharma
Merck KGaA and Pfizer’s joint drug Bavencio (avelumab) has received European approval in combination with Inlyta (axitinib) in the first-line …
Insider Interview: A roadblock for counterfeit drugs?
July 8, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Merck KGaA, blockchain, fake drugs, feature, pharma
Dr Thomas Endress, Founder, and Dr Frederic Berkermann, co-?Founder, of a new technology being developed at the Merck Innovation Center …
Pfizer & Merck’s Inlyta combo becomes first FDA-approved anti-PD-L1 therapy for kidney cancer
May 15, 2019Research and Development, Sales and Marketing FDA, Merck KGaA, Pfizer, inylta, pharma, renal cell carcinoma
The FDA has approved Bavencio (avelumab) in combination with Inlyta (axitinib) for the treatment of advanced renal cell carcinoma (RCC). …
Pfizer and Merck discontinue Phase 3 avelumab ovarian cancer trial
March 20, 2019Research and Development Merck KGaA, Pfizer, javelin, oncology, ovarian cancer
Pfizer and Merck KGaA have chosen to discontinue the Phase 3 JAVELIN trial looking into avelumab in combination with chemotherapy …
Merck KGaA enters drug discovery partnership with AI firm Itkos
March 15, 2019Medical Communications, Research and Development AI, Merck, Merck KGaA, drug discovery, pharma
Merck KGaA and artificial intelligence (AI) firm Iktos have entered into a partnership, the pair have announced, to leverage the …
Bavencio+Inlyta combo boosts progression-free survival in advanced kidney cancer
February 18, 2019Research and Development, Sales and Marketing Bavencio, Cancer, Kidney cancer, Merck KGaA, Pfizer, inlyta, pharma
New interim data for the combination of Pfizer’s Bavencio (avelumab) and Merck KGaA’s Inlyta (axitinib) have been released, showing that …
